Oxaprozin 600 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FQRQ1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,205
Award facts
- Contract value 100% obligated
- $1,205.10 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $1,205.10 to DMS Pharmaceutical Group Inc. for the supply of Oxaprozin 600 mg tablets (60-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform this order at its primary location. The contract was awarded on September 15, 2025, with a completion date of September 16, 2025, and carries no set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499.999 billion umbrella contract valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products to support military healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical pharmaceutical supplier to the Department of Defense healthcare system through consistent delivery of branded and generic prescription medications, biologics, and medical consumables. The company's federal contract portfolio demonstrates significant experience distributing specialty pharmaceuticals and medical supplies to military health facilities nationwide. This particular delivery order for Oxaprozin, a nonsteroidal anti-inflammatory medication commonly used in military and federal healthcare settings, reflects the company's ongoing role in fulfilling recurring pharmaceutical supply needs across the DLA's extensive distribution network.
Quick answers
Who was awarded contract SPE2DB25FQRQ1?
SPE2DB25FQRQ1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 15, 2025.
How much is contract SPE2DB25FQRQ1 worth?
The government has obligated $1,205 on SPE2DB25FQRQ1.
Is contract SPE2DB25FQRQ1 an order under another contract?
Yes. SPE2DB25FQRQ1 is a delivery order under SPE2DB20D9201, an indefinite delivery contract.
Was contract SPE2DB25FQRQ1 competed?
The extent of competition for SPE2DB25FQRQ1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award